Status:

COMPLETED

The Study Will Evaluate if Leuprolide Mesylate is Safe and Effective in the Treatment of Subjects With Advanced Prostate Carcinoma, When Administered as Two Injections Six Months Apart.

Lead Sponsor:

Changchun GeneScience Pharmaceutical Co., Ltd.

Conditions:

Advanced Prostate Cancer

Eligibility:

MALE

18+ years

Phase:

PHASE3

Brief Summary

Evaluate the Safety, Efficacy and Pharmacokinetics of Leuprolide Injectable Emulsion in Advanced Prostate Cancer

Eligibility Criteria

Inclusion

  • After having the scope and nature of the study explained, subjects must voluntarily sign the ICF prior to the screening visit and be willing to comply with the study requirements and cooperate with all scheduled tests
  • Male, aged ≥ 18 years old.
  • Pathologically confirmed advanced prostate cancer candidate for Androgen Deprivation Therapy, including patients those who have undergone radical treatment (surgical resection, external radiotherapy, or cryotherapy).

Exclusion

  • Received or are undergoing Androgen Deprivation Therapy (surgical castration or drug Androgen Deprivation Therapy including but not limited to gonadotropin-releasing hormone \[GnRH\] receptor agonists, GnRH receptor antagonists, estrogen and progesterone and their analogs, androgen receptor antagonists, androgen synthesis inhibitors, etc.).
  • Major surgery (including but not limited to radical prostatectomy, etc.), radiotherapy, chemotherapy, immunotherapy, cryotherapy, etc. within 4 weeks prior to the screening visit, or plan to receive the above treatments during the study
  • Receipt of any vaccination within 4 weeks prior to first dose (except COVID-19 vaccination).

Key Trial Info

Start Date :

July 12 2022

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

April 24 2024

Estimated Enrollment :

137 Patients enrolled

Trial Details

Trial ID

NCT06984159

Start Date

July 12 2022

End Date

April 24 2024

Last Update

May 22 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Sun Yat-sen Memorial Hospital, Sun Yat-sen University

Guangzhou, Guangdong, China, 510000